Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001271-68
    Sponsor's Protocol Code Number:AP32788-15-101
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-02-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-001271-68
    A.3Full title of the trial
    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
    Étude de phase 1/2 évaluant la tolérance, la pharmacocinétique et l’activité antitumorale de l’inhibiteur oral de EGFR/HER2 TAK-788 (AP32788) dans les cancers du poumon non à petites cellules
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    TAK-788 (AP32788) in Patients With Non-Small Cell Lung Cancer
    TAK-788 (AP32788) dans les cancers du poumon non à petites cellules
    A.4.1Sponsor's protocol code numberAP32788-15-101
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1217-7205
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    B.5.2Functional name of contact pointStudy Registration Call Center
    B.5.3 Address:
    B.5.3.1Street Address40 Landsdowne Street
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeMA 02139
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1866835-2233
    B.5.6E-mailGlobalOncologyMedinfo@takeda.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTAK-788
    D.3.2Product code TAK-788 (formerly AP32788)
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot yet assigned.
    D.3.9.1CAS number 1847461-43-1
    D.3.9.2Current sponsor codeTAK-788
    D.3.9.3Other descriptive nameAP32788
    D.3.9.4EV Substance CodeSUB195427
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Non-Small Cell Lung Cancer (NSCLSC)
    Cancer du Poumon Non à Petites Cellules (CPNPC)
    E.1.1.1Medical condition in easily understood language
    Non-Small Cell Lung Cancer (NSCLSC)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10029521
    E.1.2Term Non-small cell lung cancer stage IIIB
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10029522
    E.1.2Term Non-small cell lung cancer stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10059515
    E.1.2Term Non-small cell lung cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10025054
    E.1.2Term Lung cancer non-small cell stage IIIB
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10025055
    E.1.2Term Lung cancer non-small cell stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the efficacy of TAK-788, as evidenced by confirmed ORR, as assessed by the IRC, in patients with locally advanced or metastatic NSCLC harboring EGFR in-frame exon 20 insertion mutations and who have received at least 1 prior line of therapy for locally advanced or metastatic NSCLC.
    Déterminer l’efficacité du TAK-788, par le TRO confirmé, évalué par le CEI, chez les patients atteints d’un CPNPC localement avancé ou métastatique présentant des mutations à type d’insertion de l’exon 20 de l’EGFR et qui ont reçu au moins une ligne de traitement antérieure pour un CPNPC localement avancé ou métastatique.
    E.2.2Secondary objectives of the trial
    1. To further characterize the efficacy of TAK-788 as shown by confirmed ORR, as assessed by the investigator, duration of response, progression free survival (PFS), disease control rate (DCR), time to response, and overall survival (OS)
    2. To assess the safety and tolerability of TAK-788
    3. To collect sparse plasma concentration-time data of TAK 788 and its active metabolites, AP32960 and AP32914, to contribute to population PK and exposure response analyses
    4. To assess change from baseline in overall global quality of life (the Global Health Status/QoL Scale) with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and change from baseline in the Dyspnea Scale, based on the EORTC lung cancer module QLQ LC13
    1. Caractériser davantage l’efficacité du TAK-788 par le TRO confirmé, évalué par l’investigateur, la durée de la réponse, la survie sans progression (SSP), le taux de contrôle de la maladie (TCM), le délai jusqu’à la réponse et la survie globale (SG).
    2. Évaluer l’innocuité et la tolérance du TAK-788.
    3. Recueillir des données sur la concentration plasmatique en fonction du temps du TAK-788 et de ses métabolites actifs, AP32960 et AP32914, afin de contribuer aux analyses de la PK de population et de la relation exposition-réponse.
    4. Évaluer le changement par rapport à la référence en matière de qualité de vie globale à l’échelle mondiale (l’état de santé mondial/échelle de la qualité de vie) à l’aide du questionnaire sur la qualité de vie (QLQ)-C30 de l’Organisation européenne pour la recherche et le traitement du cancer (EORTC) et le changement par rapport à la référence dans l’échelle de dyspnée, en fonction du module QLQ-LC13 de l’EORTC sur le cancer du poumon.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    General
    1.Have histologically or cytologically confirmed locally advanced (and not a candidate for definitive therapy) or metastatic disease (Stage IIIB or IV). For all cohorts except Expansion Cohort 7, the locally advanced or metastatic disease is NSCLC.
    2.Must have sufficient tumor tissue available for analysis (see Study Reference Manual for specific requirements). For patients in the expansion cohorts and in the extension cohort, tumor tissue obtained after progression on the most recent prior therapy is preferred.
    3.Must have measurable disease by RECIST v1.1 (Appendix B).
    4.Male or female patients ≥18 years old. For patients in Japan, aged ≥20 years.
    5.Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (Appendix A).
    6.Minimum life expectancy of 3 months or more.
    7.Adequate renal and hepatic function as defined by the following criteria:
    a.Total serum bilirubin ≤1.5 × upper limit of normal (ULN) (≤3.0 × ULN for patients with Gilbert syndrome or if liver function abnormalities are due to underlying malignancy);
    b.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN (or ≤5 × ULN if liver function abnormalities are due to underlying malignancy);
    c.Estimated creatinine clearance ≥30 mL/min (calculated by using the Cockcroft-Gault equation);
    d.Serum albumin ≥2 g/dL; and
    e.Serum lipase/amylase ≤1.5 × ULN.
    8.Adequate bone marrow function as defined by the following criteria:
    a.Absolute neutrophil count (ANC) ≥1.5 × 109/L;
    b.Platelet count ≥75 × 109/L; and
    c.Hemoglobin ≥9.0 g/dL.
    9.Normal QT interval on screening electrocardiogram (ECG), defined as QTcF of ≤450 ms in males or ≤470 ms in females.
    10.All toxicities from prior therapy have resolved to ≤ grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0 [18]), or have resolved to baseline, at the time of first dose of TAK 788. Note: treatment-related grade >1 alopecia or treatment-related grade 2 peripheral neuropathy are allowed if deemed irreversible.
    11.Female patients who:
    •Are postmenopausal for at least 1 year before the screening visit, OR
    •Are surgically sterile, OR
    •If they are of childbearing potential, agree to practice 1 highly effective, nonhormonal method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, OR
    •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
    Male patients, even if surgically sterilized (ie, status postvasectomy), who:
    •Agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study drug, OR
    •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)

    Extension Phase specific
    1.Have a documented EGFR in-frame exon 20 insertion (including A763_Y764insFQEA, V769_D770insASV, D770_N771insNPG, D770_N771insSVD, H773_V774insNPH, or any other in-frame exon 20 insertion mutation) by a local test and sufficient tumor tissue available for central analysis (see Study Reference Manual). The EGFR exon 20 insertion mutation can be either alone or in combination with other EGFR or HER2 mutations. Note: central confirmation is not required for enrollment.
    2.Brain metastases are allowed if they have been treated with surgery and/or radiation and have been stable without requiring corticosteroids to control symptoms within 7 days prior to the first dose of TAK-788.
    3.Must have received at least 1 prior line of therapy for locally advanced or metastatic disease and no more than 2 regimens of systemic anticancer chemotherapies for locally advanced or metastatic disease.
    –Note: A systemic anticancer chemotherapy regimen will be counted if it is administered over at least 1 cycle. A new antineoplastic chemotherapy used as maintenance therapy will be counted as a new regimen. Neoadjuvant or adjuvant systemic anticancer chemotherapy will be counted as a prior regimen if completion of the (neo)adjuvant therapy occurred <12 months prior to enrollment.
    –Prior treatment with an EGFR TKI is allowed unless the patient had an objective response and subsequent progression as assessed by the investigator or treating physician during treatment with that prior TKI.
    E.4Principal exclusion criteria
    1.Previously received TAK-788.
    2.Received small-molecule anticancer therapy (including cytotoxic chemotherapy and investigational agents) ≤14 days prior to first dose of TAK 788 (except for reversible EGFR TKIs [ie, erlotinib or gefitinib], which are allowed up to 7 days prior to the first dose of TAK 788).
    3.Received antineoplastic monoclonal antibodies including immunotherapy within 28 days of the first dose of TAK-788.
    4.Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy. Note: This exclusion criterion does not apply to Expansion Cohort 7.
    5.Received radiotherapy ≤14 days prior to the first dose of TAK 788. SRS, stereotactic body radiotherapy, and palliative radiation outside the chest and brain are allowed up to 7 days prior to the first dose.
    6.Received a strong CYP3A inhibitor or strong CYP3A inducer within 2 weeks prior to first dose of TAK 788 (see Appendix C).
    7.Have undergone major surgery within 28 days prior to first dose of TAK 788. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.
    8.Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring corticosteroids to control symptoms within 7 days prior to the first dose of TAK 788.
    Note: If a patient has worsening neurological symptoms or signs due to CNS metastases, the patient needs to complete local therapy and be neurologically stable (with no requirement for corticosteroids or use of anticonvulsants) for 7 days prior to the first dose of TAK-788. Patients with no prior history of signs or symptoms of CNS metastases but who receive prophylactic steroids or anticonvulsants are allowed.
    9.Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic).
    10.Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to:
    a.Myocardial infarction (MI) within 6 months prior to the first dose of study drug;
    b.Unstable angina within 6 months prior to first dose;
    c.Congestive heart failure (CHF) within 6 months prior to first dose;
    d.History of clinically significant (as determined by the treating physician) atrial arrhythmia;
    e.Any history of ventricular arrhythmia; or
    f.Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose.
    11.Have a known history of uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure.
    12.Have prolonged QTcF interval, or being treated with medications known to be associated with the development of Torsades de Pointes (Appendix D).
    13.(Parts 1 and 2 [dose escalation and expansion cohorts] only) Have an ongoing or active infection including, but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.
    (Part 3 [extension cohort] only) Have an ongoing or active infection including, but not limited to, the requirement for IV antibiotics, or a known history of HIV. Testing is not required in the absence of history.
    (Part 3 [extension cohort] only) Hepatitis B surface antigen (HBsAg) positive patients are allowed to enroll if HBV DNA is below 1000 copies/mL in the plasma. Patients who are positive for anti-HCV antibody (HCVAb) can be enrolled but must not have detectable HCV RNA in the plasma.
    14.Currently have or have a history of interstitial lung disease, radiation pneumonitis that required steroid treatment, or drug-related pneumonitis.
    15.Female patients who are lactating and breastfeeding or have a positive urine or serum pregnancy test during the screening period. Note: Female patients who are lactating will be eligible if they discontinue breastfeeding.
    16.Have gastrointestinal illness or disorder that could affect oral absorption of TAK 788.
    17.Have any condition or illness that, in the opinion of the investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.
    E.5 End points
    E.5.1Primary end point(s)
    Confirmed ORR, as assessed by the IRC, per RECIST v1.1
    Le TRO confirmé, tel qu’évalué par le comité d’examen indépendant (CEI) selon les critères RECIST v1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary analysis of the primary endpoint, confirmed ORR as assessed by the IRC, will be performed in the full analysis set when all ongoing patients have completed their Cycle 6 disease assessment. A futility analysis will be planned for the primary endpoint when approximately 20 patients have completed their Cycle 4 disease assessment.
    L’analyse principale du critère d’évaluation principal, le TRO confirmé évalué par le CEI, sera effectuée dans l’ensemble d’analyse complet lorsque tous les patients en cours de traitement auront terminé leur évaluation de la maladie au cycle 6. Une analyse de futilité sera planifiée pour le critère d’évaluation principal lorsqu’environ 20 patients auront terminé leur évaluation de la maladie au cycle 4.
    E.5.2Secondary end point(s)
    1.Confirmed ORR, as assessed by the investigator, per RECIST v1.1
    2.Duration of response, as assessed by the IRC and the investigator
    3.Time to response, as assessed by the IRC and the investigator
    4.DCR (the percentage of patients with best response of complete response [CR], partial response [PR], or SD), as assessed by the IRC and the investigator, per RECIST v1.1
    5.PFS, as assessed by the IRC and the investigator
    6.OS
    7.Change from baseline in overall global quality of life (the Global Health Status/QoL Scale) with the EORTC QLQ-C30 and change from baseline in the Dyspnea Scale, based on the QLQ-LC13
    1. TRO confirmé, évalué par l’investigateur, selon les critères RECIST v1.1.
    2. Durée de la réponse, évaluée par le CEI et l’investigateur.
    3. Délai jusqu’à la réponse, évalué par le CEI et l’investigateur.
    4. TCM (le pourcentage de patients présentant la meilleure réponse de réponse complète [RC], de réponse partielle [RP], ou de MS), tel qu’évalué par le CEI et l’investigateur, selon les critères RECIST v1.1.
    5. SSP, évaluée par le CEI et l’investigateur.
    6. SG.
    7. Changement par rapport à la référence de la qualité de vie globale à l’échelle mondiale (l’état de santé mondial/échelle de la qualité de vie) avec le questionnaire QLQ-C30 de l’EORTC et changement par rapport à la référence dans l’échelle de dyspnée, basée sur le questionnaire QLQ-LC13.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Two-sided exact 95% binomial confidence intervals will be computed for all binary secondary endpoints, including confirmed ORR as assessed by the investigator and DCR as assessed by the IRC and the investigator. Kaplan Meier methods, including medians and confidence intervals, will be used to estimate PFS as assessed by the IRC and the investigator, duration of response as assessed by the IRC and the investigator, and OS. Descriptive statistics will be used to summarize time to response in responders and time on treatment. Patient-reported outcome assessments will be assessed at each cycle using descriptive summary statistics.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA35
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    China
    France
    Germany
    Italy
    Japan
    Korea, Republic of
    Spain
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study (completion) date is approximately 3 years after the last patient has enrolled in Part 3 (the extension cohort) or when all patients have completed all study visits or have otherwise discontinued from the study.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 11
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state7
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 91
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects will revert to standard clinical management as directed by attending personal physician.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-04-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-10-09
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 04:03:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA